SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection — Stella

Recruiting

Back to SCID, X-Linked trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

China

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong

Guilin Hospital of Chinese Traditional and Western Medicine, Guilin, Guangxi

Key details

Phase

Early testing / Safety & dosing

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment target

~10 participants

Started

June 2024

Primary completion

December 2026

Age range

1 Month – 1 Year

Sex

Male only

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov